Kolltan Raises $60 Million Series D, But Keeps Mum About Cancer Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Never a company known to offer much detail about its plans, Kolltan has raised a $60 million Series D led by an undisclosed global institutional asset manager. Its lead program is in Phase I with the biotech planning a Phase II program combining KTN3379 with other cancer therapies.
You may also be interested in...
Deerfield’s Private Designs
Deerfield Management has a blank slate with its new $1.6 billion fund for health care investment, the third that it’s dedicated to private company investment and public company structured financing. The hedge fund is trying to reprise the performance of its prior two Private Design funds, for which it claims only one loss thus far in each.
Kolltan Approaching First IND Submission For RTK-Targeted Oncology Drug Candidate
Having raised about $75 million in venture funding since its 2007 inception, Kolltan Pharmaceuticals is getting closer to the clinic with novel oncology candidates targeting receptor tyrosine kinases.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.